Chief Executive Officer, Chief Financial Officer; Board Chairman
Mr. Ehrlich is a co-founder of Innovation and serves as Chief Financial Officer and Chief Executive Officer for the company. He also is Board Chairman. Mr. Ehrlich has over 25 years of executive leadership experience in building and managing emerging growth companies. Prior to joining Innovation, Mr. Ehrlich served as Chief Financial Officer and Director of Nanoviricides, a publicly-traded company developing nanotechnology-based anti-viral medicines. Mr. Ehrlich also served in various management roles—as CEO, President, CFO, Director—while at StatSure Diagnostic Systems, Inc., a diagnostic specialty firm with a focus on HIV testing. Mr. Ehrlich is a Certified Public Accountant and received a BBA degree from Bernard Baruch College of the City University of New York.
Arthur P. Bertolino, MD, PHD, MBA
President and Chief Medical Officer; Board Member
Dr. Bertolino MD, PhD, MBA, joined the Company as President and Chief Medical Officer in June 2016. Dr. Bertolino held several key positions at Novartis Institutes for Biomedical Research (“NIBR”) from 2008 to 2013, including Vice President of Dermatology and Vice President & Global Head of Translational Medicine for Dermatology. During his time at NIBR, Dr. Bertolino was integral to the marketing approval of Ilaris (canakinumab) in the United States, European Union and Switzerland. He also led the early clinical program of Cosentyx™ (secukinumab) and late stage supportive submission studies. In addition, Dr. Bertolino held positions as Senior Medical Director and Senior Director of Dermatology at Pfizer, Inc. from 2003 to 2007. Among other accomplishments at Pfizer, he led clinical programs for over a half-dozen new chemical entities involving Phase 1 and Phase 2 studies and contributed to planning for Phase 3 studies. Dr. Bertolino led FDA clinical interactions at entitlement meetings for Pfizer’s dermatology products and served as Pfizer’s dermatology spokesperson. Dr. Bertolino served as Chief Medical Officer and Vice President of Medical Affairs at Peplin, Inc. from 2007 to 2008, where he led Phase 2 programs and designed and drove initial Phase 3 programs that contributed to FDA approval of Picato (ingenol mebutate). Dr. Bertolino also held the position of Executive Vice President and Chief Medical Officer at Revance Therapeutics from 2014 to 2016, where he, among other responsibilities, supervised all aspects of clinical staff and programs and regulatory affairs. Dr. Bertolino earned a BS in Chemistry/Biochemistry from SUNY Stony Brook, an MD and PhD in Pharmacology from The Johns Hopkins University School of Medicine, and an MBA from the University of Michigan Stephen M. Ross School of Business.
Barry SchecHter, MD, FAAO
Independent Board Member
Dr. Schechter is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Prior, he was co-founder and Chief Executive Officer (CEO) of Pediavision, a company dedicated to saving children’s eyesight. He also is a consultant for Gerson Lehrman Group. Dr. Schechter’s clinical focus involves diseases of the ocular surface, including dry eyes, allergies, infection, corneal, refractive and cataract surgery, and glaucoma. He also serves on the Editorial Board for Advanced Ocular Care. Dr. Schechter has reviewed numerous articles for leading ophthalmology journals, lectures worldwide, and consults for various pharmaceutical companies. Dr. Schechter graduated from City University of New York and Brooklyn College, and received a MD from SUNY Downstate Medical Center.
Zorik Spektor, MD, FAAP
Independent Board Member
Dr. Spektor is a Fellowship-trained and Board-certified Pediatric Otolaryngologist and Head and Neck Surgeon. He has served on advisory boards for several medical device and pharmaceutical companies and been involved in significant advances in his field. Dr. Spektor currently serves as Director of The Center for Pediatric ENT – Head and Neck Surgery, in Boynton, Florida. He is also a Voluntary Assistant Professor of Surgery at the Department of Otolaryngology, University of Miami, and an Affiliate Clinical Assistant Professor of Biomedical Science at Florida Atlantic University. He is a Fellow of the American Academy of Otolaryngology – Head and Neck Surgery and American Academy of Pediatrics. Dr. Spektor received a BS from Cornell University, and a MD from Albany Medical College of Union University.